‘The Crohn’s Stricture CS3M Study’ (CS3M)

  • Research type

    Research Study

  • Full title

    Characterising the Effects of Relieving Stricture Obstruction by Ileocolonic Stenting - A Pilot Study into Motility, Microbiomics & Metabolomics in Crohn’s Disease

  • IRAS ID

    252808

  • Contact name

    Angela Shone

  • Contact email

    sponsor@nottingham.ac.uk

  • Sponsor organisation

    Research and Innovation - University of Nottingham

  • Duration of Study in the UK

    1 years, 6 months, 1 days

  • Research summary

    Crohn's Disease (CD) patients frequently experience abdominal pain, nausea, and diarrhoea. These symptoms may result from ‘narrowings’ within the bowel known as ‘strictures'. Crohn’s patients who have intestinal surgery experience ‘stricturing’ (the formation of strictures) more often. The ‘CS3M Crohn’s Stricture Study’ will give new insights into ‘strictures’ in this context. There are many unanswered questions. It is unclear how strictures affect bowel contraction, bacteria within the gut and bacterial by-products.

    Each Crohn’s patient in the study will have a previously identified stricture. A number of different treatment modalities exist - including surgical resection, stricturoplasty and endoscopic balloon dilatation. Intestinal ‘stenting’ is one of the available therapies. It involves the endoscopic placement of an opening device, known as a ‘stent’, into the affected area. All modalities and their risk profiles will be presented to patients. Should a patient choose to undergo stent therapy, they will then be invited to take part in the study.

    Four separate aspects of intestinal strictures in CD will be investigated:

    1. How stenting of strictures affects the movement of the bowel (a.k.a. motility).
    2. How stenting of strictures affects the bacterial content of the gut (a.k.a. microbiome).
    3. How stenting of the strictures affects bacterial by-products from the gut (a.k.a. metabolomics).
    4. The clinical impact of CD stricture stenting.

    Each patient will undergo a Magnetic Resonance (MR) scan assessing intestinal motility before and after stent treatment. Stool samples will be collected prior to and following stenting. These stool samples will be analysed for bacterial content and by-products. The novel insights into strictures in CD will be delivered by data produced by motility, microbiome, and metabolomic analysis. This research will generate the first global report such findings.

  • REC name

    HSC REC B

  • REC reference

    18/NI/0241

  • Date of REC Opinion

    24 Dec 2018

  • REC opinion

    Further Information Favourable Opinion